

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
Investissement Quebec	04/12/2012
RECEIVING PARTY DATA	
Name:	Gemin X Pharmaceuticals Canada Inc.
Street Address:	3576 Avenue Du Parc, Suite 4310
City:	Montreal, Quebec
State/Country:	CANADA
Postal Code:	H2X 2H7
PROPERTY NUMBERS Total: 20	
Property Type	Number
Patent Number:	6358687
Patent Number:	6294332
Patent Number:	6407244
Patent Number:	6602879
Patent Number:	7491745
Patent Number:	7144912
Patent Number:	7425553
Patent Number:	7709477
Patent Number:	7217844
Patent Number:	7230139
Application Number:	10943441
Application Number:	10392202
Application Number:	12176123
Application Number:	13171891
Application Number:	11895012

CH \$800.00 6358687

Application Number:	11794488
Application Number:	11825194
Application Number:	60975488
Application Number:	12237755
Application Number:	12410930

CORRESPONDENCE DATA

Fax Number:

Email: rona.nardone@tevapharm.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Rona A Nardone

Address Line 1: 41 Moores Road

Address Line 4: Frazer, PENNSYLVANIA 19355

ATTORNEY DOCKET NUMBER:

GEMINX

NAME OF SUBMITTER:

Rona A. Nardone

Total Attachments: 12

- source=IQ Confirmatory Release executed#page1.tif
- source=IQ Confirmatory Release executed#page2.tif
- source=IQ Confirmatory Release executed#page3.tif
- source=IQ Confirmatory Release executed#page4.tif
- source=IQ Confirmatory Release executed#page5.tif
- source=IQ Confirmatory Release executed#page6.tif
- source=IQ Confirmatory Release executed#page7.tif
- source=IQ Confirmatory Release executed#page8.tif
- source=IQ Confirmatory Release executed#page9.tif
- source=IQ Confirmatory Release executed#page10.tif
- source=IQ Confirmatory Release executed#page11.tif
- source=IQ Confirmatory Release executed#page12.tif

Confirmatory Release and Discharge of Security Interest

WHEREAS, pursuant to a security agreement between the Investissement Québec, acting as Lender and Gemin X Pharmaceuticals Canada Inc./Gemin X Pharmaceutiques Canada Inc. (formerly Gemin X Biotechnologies Inc.) dated May 21, 2004 as amended on August 17, 2006, and February 21, 2006 (the "Agreements"), a security interest was granted in favor of the Lender in and to the patents, patent applications, and any improvements, divisionals, continuations, renewals, reissues, extensions and continuations-in-part thereof, as set forth in "Schedule A" and the trademark registrations as set forth in "Schedule B" (the "Intellectual Property");

AND WHEREAS the Leader has received payment in full under the Agreements and has released all of its security interest in and to the Intellectual Property pursuant to a letter agreement dated April 15, 2011, and wishes to confirm such release by having this Confirmatory Release and Discharge of Security Interest recorded in, and the Agreements removed from, the applicable records of the United States Patent and Trademark Office or the applicable records in any other jurisdiction;

NOW THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and adequacy of which are acknowledged herein, the Lender:

1. confirms that it has not assigned or otherwise disposed of its security interest in and to the Intellectual Property; and
2. confirms that it has released and discharged, and does hereby release and discharge, the full interest granted to the Lender in and to the Intellectual Property.

IN WITNESS WHEREOF, the Lender has caused this Confirmatory Release and Discharge of Security Interest to be duly executed by an authorized officer.

Executed at Montreal this 13^e day of April, 2012.


Signatures:

WITNESS:

INVESTISSEMENT QUÉBEC



Name: SYLVAIN OUELLET
Title: COORDINATOR -
SPECIAL ACCOUNTS



Name: ALEJANDRO MORALES
Title: DIRECTOR, SPECIAL ACCOUNTS

Confirmatory Release and Discharge

WITNESS:



Name: *Zena Nardone*
Title: *Assoc. Director*

GEMIN X PHARMACEUTICALS CANADA INC. /
GEMIN X PHARMACEUTIQUES CANADA INC.



Name: *Ross J. Oakley*
Title: *Vice President*

EXHIBIT A

Patents

Title	Jurisdiction	Patent number or application number
<i>Composition and methods for monitoring the binding of A1/UP1 to telomeric DNA sequences and telomerase RNA, and for measuring the effect of this binding on telomere extension and protection</i>	United States	Patent No. 6,358,687
<i>Composition and methods for monitoring the binding of A1/UP1 to telomeric DNA sequences and telomerase RNA, and for measuring the effect of this binding on telomere extension and protection</i>	Europe - validated in UK / Ireland / Germany / and France	00106572.1 Patent No. 1043404 Germany Patent No. 60043085.5
<i>Composition and methods for monitoring the binding of A1/UP1 to telomeric DNA sequences and telomerase RNA, and for measuring the effect of this binding on telomere extension and protection</i>	Canada	2,302,134
<i>Composition and methods for modulating the length of telomeres</i>	Europe	97928088.0
<i>Composition and methods for modulating the length of telomeres</i>	Canada	2,259,389
<i>Compositions and methods for modulating the length of</i>	United States	Patent No. 6,294,332

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>telomeres</i>		
<i>Methods and Composition for Treating Neoplasia Relating to hnRNP A1 and A2 Nucleic Acid Molecules</i>	Canada	2,487,427
<i>Methods and Compositions for Treating Neoplasia Relating to hnRNP A1 and A2 Nucleic Acid Molecules</i>	Europe	3727087.3 - 1212
<i>Methods and Compositions for Treating Neoplasia Relating to hnRNP A1 and A2 Nucleic Acid Molecules</i>	Japan	2004-510423
<i>Methods and compositions relating to HNRNP A1, A1B, A2 and B1 nucleic acid molecules</i>	United States	10/943,441
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	United States	Patent No. 6,407,244
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	United States	Patent No. 6,602,879
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	United States	11/581,920 7,491, 745
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	United States	10/392,202

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Australia	200129912 2005201730 (DIV)
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Brazil	P10107912-3
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Canada	2398173
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	China	1807066.3
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Czech Republic	PV2002-2604
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Europe	01902193 04003643.6 (DIV)
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Hong Kong	310830.1
<i>Pyrrole-type compounds, compositions and methods for treating cancer of viral diseases</i>	Israel	150817
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	Japan	14-560990

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	Republic of Korea	2002-7009667
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	Mexico	2002-007271 2005/005397 (DIV)
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	New Zealand	520361
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	Norway	20023486
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	Poland	P356932
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	Slovakia	PP1095-2002
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer of Viral Diseases</i>	South Africa	2002/5838
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer, Treating Viral Diseases and Causing Immunosuppression</i>	Canada	2453636

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer, Treating Viral Diseases and Causing Immunosuppression</i>	Europe Validated in Germany, Spain, France, UK and Italy	Patent No. 1427722 Germany Patent No. 60223571.5
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer, Treating Viral Diseases and Causing Immunosuppression</i>	Japan	15-513969
<i>Pyrrole-type Compounds, Compositions and Methods for Treating Cancer, Treating Viral Diseases and Causing Immunosuppression</i>	United States	Patent No. 7,144,912
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	United States	10/857,458 Patent No. 7,425,553
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	United States	12/176,161 Patent No. 7,709,477
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	United States	12/176,123
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	United States	13/171,891
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Australia	2004242928

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Brazil	PI0410870-1
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Canada	2,527,583
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	China	200480022292.3 Patent No. 1832939A
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Europe Validated in all member states of the European Patent Organization and extension states	04735171.3 Patent No. 1644363
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Hong Kong	06105160.7 Patent no. 1082737A
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	India	5563/DELNP/2005 Patent No. 238221
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Israel	172189
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Japan	100065755

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	South Korea	10-2005-7022973
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Mexico	PA/a/2005/012799 Patent No. 271025
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Norway	20056057
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	New Zealand	543897 Patent No. 543897
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Russia	2005141553 Patent No. 2360913
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	Singapore	2005507649-2 Patent No. 117325
<i>Triheterocyclic compounds, compositions and methods for treating cancer or viral diseases</i>	South Africa	Patent No. 2005/09718
<i>Methods of Treating Rheumatoid Arthritis Using Triheterocyclic Compounds</i>	United States	11/895,012
<i>Methods of Treating Rheumatoid Arthritis Using Triheterocyclic Compounds</i>	EPC	06705185.4

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
<i>Dipyrrole Compounds, Compositions and Methods for Treating Cancer or Viral Diseases</i>	United States	11/794,488
<i>Dipyrrole Compounds, Compositions and Methods for Treating Cancer or Viral Diseases</i>	EPC	5823816.3
<i>Dipyrrole Compounds, Compositions and Methods for Treating Cancer or Viral Diseases</i>	Japan	2007-547126
<i>Methods for Treating or Preventing Anemia or Thrombocytopenia Using a Triheterocyclic Compound</i>	Canada	2,563,116
<i>Methods for Treating or Preventing Anemia or Thrombocytopenia Using a Triheterocyclic Compound</i>	United States	11/825,194
<i>Diterpenoid Compounds, Compositions Thereof and Their Use as Anti-Cancer or Anti-Fungal Agents</i>	United States	10/725,629 7,217,844
<i>Diterpenoid Compounds, Compositions Thereof and Their Use as Anti-Cancer or Anti-Fungal Agents</i>	United States	10/865,262 7,230,139
<i>Methods for effecting NAD⁺ levels using pyridyl cyanoguanidines and prodrugs</i>	United States	60/975,488
<i>Compositions and methods for effective NAD⁺ levels using a nicotinamide phosphoribosyl transferase inhibitor</i>	United States	12/237,755

Confirmatory Release and Discharge

Title	Jurisdiction	Patent number or application number
Compositions and methods for effective NAD ⁺ levels using a nicotinamide phosphoribosyl transferase inhibitor	United States	12/410,930
Compositions and methods for effective NAD ⁺ levels using a nicotinamide phosphoribosyl transferase inhibitor	Canada	2,701,071
Compositions and methods for effective NAD ⁺ levels using a nicotinamide phosphoribosyl transferase inhibitor	EPC	08857613.7

Confirmatory Release and Discharge

Schedule B (Trademarks)

Owner	Title	Jurisdiction	Application number / Registration number	Filing Date
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 042 for Services	United States	77/266111 3,585,333	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 042 for Services	Canada	1385313 TMA762,627	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 042 and 045 for Services	Europe	6706171 6706171	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	United States	77/265,901 4,002,660	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	Canada	1385315 TMA769,561	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	Europe	6706171 6706171	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	China	6568794	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	China	9163797	March 2, 2011
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	Hong Kong	301061054 301061054	August 28, 2007
Gemin X Pharmaceuticals Canada Inc.	Mark: GEMIN X International Class: 005 for Goods	Japan	014654/2008 5144330	August 28, 2007